T. Rowe Price Associates’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $162M | Sell |
|
|||||
|
2025
Q2 | $154M | Sell |
|
|||||
|
2025
Q1 | $180M | Sell |
|
|||||
|
2024
Q4 | $182M | Sell |
|
|||||
|
2024
Q3 | $156M | Sell |
|
|||||
|
2024
Q2 | $241M | Buy |
|
|||||
|
2024
Q1 | $214M | Buy |
|
|||||
|
2023
Q4 | $89.9M | Buy |
|
|||||
|
2023
Q3 | $24.9M | Buy |
|
|||||
|
2023
Q2 | $12.8M | Buy |
|
|||||
|
2023
Q1 | $11.4M | Sell |
|
|||||
|
2022
Q4 | $16M | Buy |
|
|||||
|
2022
Q3 | $3.03M | Buy |
|
|||||
|
2022
Q2 | $3.04M | Sell |
|
|||||
|
2022
Q1 | $4.41M | Sell |
|
|||||
|
2021
Q4 | $4.11M | Sell |
|
|||||
|
2021
Q3 | $4.61M | Sell |
|
|||||
|
2021
Q2 | $7.43M | Sell |
|
|||||
|
2021
Q1 | $10M | Sell |
|
|||||
|
2020
Q4 | $19M | Sell |
|
|||||
|
2020
Q3 | $20.9M | Buy |
|
|||||
|
2020
Q2 | $16.3M | Buy |
|
|||||
|
2020
Q1 | $3.12M | Sell |
|
|||||
|
2019
Q4 | $4.32M | Sell |
|
|||||
|
2019
Q3 | $12.3M | Sell |
|
|||||
|
2019
Q2 | $24.2M | Sell |
|
|||||
|
2019
Q1 | $32.8M | Buy |
|
|||||
|
2018
Q4 | $29.4M | Sell |
|
|||||
|
2018
Q3 | $107M | Sell |
|
|||||
|
2018
Q2 | $159M | Buy |
|
|||||
|
2018
Q1 | $21.7M | Buy |
|